Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-term experience with indapamide.

S Beling, R A Vukovich, E S Neiss

    American Heart Journal
    |July 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    New criteria for efficient Raman and Brillouin amplification of laser beams in plasma.

    Scientific reports·2020
    Same author

    Physical activity accrued as part of public transport use in England.

    Journal of public health (Oxford, England)·2018
    Same author

    Two synchronous non small cell lung carcinomas with different morphologies in the same lobe.

    Journal of surgical case reports·2014
    Same author

    Commentary on the ISSOP policy statement on the UNCRC and health.

    Child: care, health and development·2014
    Same author

    Use of impedance ratios to assess hand swelling in lymphoedema.

    Phlebology·2012
    Same author

    Housing and respiratory health at older ages.

    Journal of epidemiology and community health·2012
    Same journal

    Stratified Medicine with Eplerenone for Myocardial Infarction or Injury and No obstructive Coronary Arteries: A Registry-Based Basket Trial.

    American heart journal·2026
    Same journal

    Revised Lipid-Lowering Therapy Guidelines in a Nationally Representative Sample.

    American heart journal·2026
    Same journal

    Cardiometabolic Health of Low- and Higher-Income Adults in the United States, 2009-2023.

    American heart journal·2026
    Same journal

    Moving Beyond Technical Capability to Regulatory Integration for Digital Health Technology Devices-Brief Communication from the Cardiovascular Sciences Research Consortium.

    American heart journal·2026
    Same journal

    THE SOCIETY OF CRITICAL CARE CARDIOLOGY - RATIONALE, BLUEPRINT, AND LESSONS LEARNED IN THE CREATION OF A NEW MULTIDISCIPLINARY PROFESSIONAL ORGANIZATION.

    American heart journal·2026
    Same journal

    DOAC Score Among Patients Receiving Vitamin K Antagonists.

    American heart journal·2026
    See all related articles

    Indapamide, a diuretic, effectively controls mild to moderate hypertension long-term. This study found indapamide (2.5 mg) comparable to hydrochlorothiazide (50 mg) in safety and efficacy for hypertension management.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Clinical Trials

    Background:

    • Hypertension is a prevalent cardiovascular risk factor.
    • Effective long-term management of hypertension is crucial.
    • Diuretics are a cornerstone of antihypertensive therapy.

    Purpose of the Study:

    • To evaluate the safety and efficacy of indapamide for long-term hypertension control.
    • To compare indapamide with hydrochlorothiazide in treating mild to moderate hypertension.
    • To assess the safety profile of indapamide over extended treatment periods.

    Main Methods:

    • Two randomized, double-blind, multicenter trials were conducted.
    • Data from 20 study sites were pooled for analysis.
    • Patients received either indapamide (2.5 mg daily) or hydrochlorothiazide (50 mg daily).

    Related Experiment Videos

    Main Results:

    • Both indapamide and hydrochlorothiazide significantly reduced systolic and diastolic blood pressure within 8 weeks.
    • Therapeutic success rates were similar: 56% for indapamide and 53% for hydrochlorothiazide.
    • Adverse reactions and laboratory assessments showed no significant differences between groups.

    Conclusions:

    • Indapamide (2.5 mg daily) is safe and effective for long-term management of mild to moderate hypertension.
    • Indapamide demonstrates comparable efficacy and safety to hydrochlorothiazide (50 mg daily).
    • Extended treatment up to 36 months with indapamide showed no increased adverse effects.